Thomas Kleemann

Dr. Thomas Kleemann

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2009 in EP Europace
Verified
Journal Article
Open access
PDF file
TKThomas Kleemann
Thomas Kleemann
TBTorsten Becker
Torsten Becker
MSMargit Strauss
Margit Strauss
NDNgoc Dyck
Ngoc Dyck
UWUdo Weisse
Udo Weisse
KSKarlheinz Seidl
Karlheinz Seidl
This study was designed to evaluate the prevalence of bacterial colonization of generator pockets in implantable cardioverter defibrillator (ICD) patients without signs of infection and to analyse the impact of bacterial colonization on the incidence of device infection during follow-up. In 122 ICD patients undergoing generator replacement or surgical lead revision between January 2006 and July 2008, microbiological cultures of generator pockets and extracted leads were consecutively obtained. Patients with clinical evidence of a device infection were excluded. Positive cultures from the generator pocket and leads were found in 40 (33%) patients. The most common bacteria isolated were coagulase negative staphylococci (68%). During a median follow-up time of 203 days after the revision device infection occurred in three [7.5%, confidence interval (CI) 1.6–20.4%] patients with a positive culture vs. two (2.4%, CI 0.3–8.5%) patients with a negative culture ( P = 0.33). Time from revision to infection was 108 ± 73 days in patients with positive culture vs. 60 ± 39 days in patients with negative culture ( P = 0.50). A third of ICD patients undergoing generator replacement or lead revision have an asymptomatic bacterial colonization of generator pockets. After revision 7.5% of these patients develop a device infection with the same species of microorganism.

1 December 2009 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
TKThomas Kleemann
Thomas Kleemann
TBTorsten Becker
Torsten Becker
MSMargit Strauss
Margit Strauss
SSSteffen Schneider
Steffen Schneider
KSKarlheinz Seidl
Karlheinz Seidl

2 October 2008 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
TKThomas Kleemann
Thomas Kleemann
TBTorsten Becker
Torsten Becker
MSMargit Strauss
Margit Strauss
SSSteffen Schneider
Steffen Schneider
KSKarlheinz Seidl
Karlheinz Seidl
To evaluate the prevalence and clinical impact of left atrial (LA) thrombus and dense spontaneous echo contrast (SEC) in patients with atrial fibrillation (AF) and low CHADS 2 score undergoing cardioversion. A total of 295 consecutive patients with non-valvular AF and a CHADS 2 score of 0 or 1 from the prospective single-centre registry ANTIK, who underwent transoesophageal echocardiography before cardioversion, were included in the study. Median follow-up was 5 years. LA thrombus was present in 3% and dense SEC in 8% of patients. Independent predictors for the presence of thrombus or dense SEC were ejection fraction (EF) <40% and LA diameter ≥50 mm. In anticoagulated patients, thrombus and dense SEC were not independently associated with an increased risk for stroke or death during the 5 year follow-up (OR 1.55, 95% CI 0.50–4.83). Despite a low CHADS 2 score of 0/1, 3% of patients have LA thrombus and 8% of patients have dense SEC. Independent predictors for the presence of thrombus and dense SEC were EF <40% and LA dimension ≥50 mm. Thus, echocardiography might be a useful tool for further risk stratification in patients with low CHADS 2 score.

1 August 2008 in American Heart Journal
Verified
Journal Article
Closed access
TKThomas Kleemann
Thomas Kleemann
CJClaus Juenger
Claus Juenger
AGAnselm Kai Gitt
Anselm Kai Gitt
RSRudolf Schiele
Rudolf Schiele
SSSteffen Schneider
Steffen Schneider
KSKarlheinz Seidl
Karlheinz Seidl

3 March 2010 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
TKThomas Kleemann
Thomas Kleemann
TBTorsten Becker
Torsten Becker
MSMargit Strauss
Margit Strauss
NDNgoc Dyck
Ngoc Dyck
SSSteffen Schneider
Steffen Schneider
KSKarlheinz Seidl
Karlheinz Seidl

16 February 2015 in EP Europace
Verified
Journal Article
Open access
PDF file
TKThomas Kleemann
Thomas Kleemann
MSMargit Strauss
Margit Strauss
KKKleopatra Kouraki
Kleopatra Kouraki
RZRalf Zahn
Ralf Zahn
In patients with an implantable cardioverter-defibrillator (ICD), ICD shocks due to ventricular tachycardia (VT) or ventricular fibrillation (VF) have been associated with an increased mortality. It is not known whether patients with antitachycardia pacing (ATP)-terminated VT/VF episodes have a similar worse outcome. The aim of this study was to evaluate the clinical course and prognostic impact of ATP-terminated episodes on mortality in ICD patients. A total of 1398 consecutive patients of the prospective single-centre ICD-registry Ludwigshafen who underwent an ICD implantation between 1992 and 2008 for primary or secondary prevention of sudden cardiac death were analysed. Patients treated with ATP were compared with patients with appropriate ICD shocks or patients without any appropriate ATP or ICD shock. During the median follow-up time of 6 years, 749 (54%) patients experienced 17 827 episodes of VT or VF which were terminated by ATP in 74% and by shock in 26% of patients. In approximately half (n = 321/749) of those patients with VT/VF, the first episode was terminated by ATP. In a multivariate analysis adjusted for different baseline confounding parameters, the occurrence of first ATP therapy was associated with a higher mortality rate [hazard ratio (HR) 2.60, 95% confidence interval (CI) 2.02–3.35]. When excluding all patients with appropriate ICD shocks first ATP therapy remained associated with a worse prognosis (HR 1.92, 95% CI 1.38–2.67). In ICD patients, about three-fourths of ventricular arrhythmias are terminated by ATP. The occurrence of ATP-terminated episode is associated with an increased mortality rate.